These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 8193523)

  • 1. Dose linearity of clonidine after transdermal application.
    Wallenstein G; Gladigau V
    Clin Auton Res; 1993 Dec; 3(6):369-72. PubMed ID: 8193523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Determination of clonidine in rabbit plasma by HPLC-MS].
    Ke GM; Zhang EH; Wang L; Zhang Q; Du HG; Guo HY
    Yao Xue Xue Bao; 2004 May; 39(5):367-9. PubMed ID: 15338881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioequivalence and adhesion evaluation of transdermal clonidine following a change in excipient supplier.
    Ehrlich J; Beck B; Thiedmann R; Marzin K; MacGregor T
    Int J Clin Pharmacol Ther; 2016 Oct; 54(10):816-24. PubMed ID: 27390050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo characterization of a newly developed clonidine transdermal patch for treatment of attention deficit hyperactivity disorder in children.
    Ke GM; Wang L; Xue HY; Lu WL; Zhang X; Zhang Q; Guo HY
    Biol Pharm Bull; 2005 Feb; 28(2):305-10. PubMed ID: 15684489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influences of bathing and hot weather on the pharmacokinetics of a new transdermal clonidine, M-5041T.
    Fujimura A; Sasaki M; Harada K; Kumagai Y; Ohashi K; Ebihara A
    J Clin Pharmacol; 1996 Oct; 36(10):892-6. PubMed ID: 8930775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of clonidine as transdermal therapeutic system: the international clinical trial experience.
    Lowenthal DT; Saris S; Paran E; Cristal N; Sharif K; Bies C; Fagan T
    Am Heart J; 1986 Oct; 112(4):893-900. PubMed ID: 3532747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacokinetics of clonidine.
    Lowenthal DT; Matzek KM; MacGregor TR
    Clin Pharmacokinet; 1988 May; 14(5):287-310. PubMed ID: 3293868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rate and extent of absorption of clonidine from a transdermal therapeutic system.
    Toon S; Hopkins KJ; Aarons L; Rowland M
    J Pharm Pharmacol; 1989 Jan; 41(1):17-21. PubMed ID: 2565958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of nitroglycerin and clonidine delivered by the transdermal route.
    Shaw JE
    Am Heart J; 1984 Jul; 108(1):217-23. PubMed ID: 6428208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics of a new transdermal clonidine, M-5041T, in healthy subjects.
    Fujimura A; Ebihara A; Shiga T; Kumagai Y; Ohashi K; Nakashima H; Kotegawa T
    J Clin Pharmacol; 1993 Dec; 33(12):1192-200. PubMed ID: 8126254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the pharmacokinetics, pharmacodynamics, and safety of oral (Catapres) and transdermal (M-5041T) clonidine in healthy subjects.
    Fujimura A; Ebihara A; Ohashi K; Shiga T; Kumagai Y; Nakashima H; Kotegawa T
    J Clin Pharmacol; 1994 Mar; 34(3):260-5. PubMed ID: 8021335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of transdermal clonidine in chronic hemodialysis patients.
    Rosansky SJ; Johnson KL; McConnell J
    Clin Nephrol; 1993 Jan; 39(1):32-6. PubMed ID: 8428405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of application site of a new transdermal clonidine, M-5041T, on its pharmacokinetics and pharmacodynamics in healthy subjects.
    Ebihara A; Fujimura A; Ohashi K; Shiga T; Kumagai Y; Nakashima H; Kotegawa T
    J Clin Pharmacol; 1993 Dec; 33(12):1188-91. PubMed ID: 8126253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antihypertensive effects of a new transdermal delivery system for clonidine (M-5041T) in spontaneously hypertensive rats.
    Ishii R; Naruse T; Tagawa T; Yamahata T; Dote S; Hamada K; Ishida T; Funabiki K; Namba K
    Arch Int Pharmacodyn Ther; 1994; 327(3):294-308. PubMed ID: 7848013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antihypertensive effects of a new transdermal delivery system for clonidine in genetic and experimental hypertensive rats.
    Ishii R; Tagawa T; Ishida T; Naruse T
    Arzneimittelforschung; 1996 Mar; 46(3):261-8. PubMed ID: 8901146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the antihypertensive effect of TTS clonidine by multiple 24-hour automatic blood pressure monitoring.
    Mancia G; Parati G; Pomidossi G; Malaspina D; Colombo A; Camesasca C; Groppelli A; Casadei R; Zanchetti A
    J Cardiovasc Pharmacol; 1987; 10 Suppl 12():S187-93. PubMed ID: 2455177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro/in vivo functionality of Catapres-TTS.
    Enscore DJ; Osborne JL; Shaw JE
    Methods Find Exp Clin Pharmacol; 1989 Mar; 11(3):173-8. PubMed ID: 2657275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Skin pretreatment and the use of transdermal clonidine.
    Ito MK; O'Connor DT
    Am J Med; 1991 Jul; 91(1A):42S-49S. PubMed ID: 1831005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of a HPLC-ESI MS/MS method for the determination of clonidine in human plasma and its application in a bioequivalence study in Chinese healthy volunteers.
    Zhuang J; Chen J; Wang X; Pang Y; Bi H; Huang L; Zeng G; Liao X; Ma Z; Chen X; Zhong G; Huang M; Zhao X
    Biomed Chromatogr; 2015 Oct; 29(10):1506-13. PubMed ID: 25776729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of a transdermal delivery system for antihypertensive therapy. Part 1.
    Sclar DA; Skaer TL; Chin A; Okamoto MP; Gill MA
    Am J Med; 1991 Jul; 91(1A):50S-56S. PubMed ID: 1907801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.